Press releases

5 Apr 2024

Acquisition of own shares

4 Apr 2024

FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

29 Mar 2024

Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees

22 Mar 2024

UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa

15 Mar 2024

UCB announces changes on Board of Directors

13 Mar 2024

UCB successfully completes institutional Eurobond issue

Press releases

Press releases

Search Press releases

Acquisition of own shares

FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees

UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa

UCB announces changes on Board of Directors

UCB successfully completes institutional Eurobond issue

Choose a Country

UCB and Ailux Biologics Join Forces to Transform Biologics Research

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in...

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Acquisition of own shares

FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees

UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa

UCB announces changes on Board of Directors

UCB successfully completes institutional Eurobond issue

Choose a Country